BioSpace News Archive

Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on therapeutics for acute care settings, (“Baudax Bio” or the “Company”) today announced that it will report full year 2020 financial results on Tuesday, February 16, 2021. Baudax’s management team will host a conference call and webcast at 8:00 a.m. ET on Tuesday, February 16, 2021 to discuss the financial results and recent operational highlights.

Provides Milestones for Attaining NICE Guidance, Including Addition of UroShield to the NHS Supply Chain; Process Completion and Recommendation Expected in Q1 2022

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the “Company” or “Regulus”), today announced it has completed enrollment of the first cohort of patients into its Phase 1b clinical study of RGLS432

Elekta announced today that the United States Department of Veterans Affairs (VA) National Radiation Oncology Program is poised to pair its major radiotherapy quality program with Elekta’s (EKTA-B.ST)

Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company dedicated to providing therapies to treat the global rise of bacterial and viral infectious diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for PhageBank™

SciSparc Ltd. (formerly known as Therapix Biosciences Ltd.) (OTCQB: TRPXY), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, today announced it has entered an agreement with Procaps

The Foundation for Advancing Pediatric Orthopaedics is pleased to announce that after a national search, Caroline Eaton has been hired to serve as the organization’s inaugural executive director, effective February 8, 2021.

Celon Pharma S.A. today announced the successful completion of its Phase 1A trial of its JAK/ROCK kinases dual inhibitor, CPL’116.

Doximity, the largest U.S. professional medical network, today announced the appointment of Tim Cabral to its board of directors and chair of the company’s audit committee.

Ubiquigent Limited (Ubiquigent) announced today that it has entered into a license agreement with Medivir AB (Nasdaq Stockholm: MVIR) for Medivir’s preclinical USP7 research program.